No significant difference in neutrophil activation found among three H2RAs.
BACKGROUND
Even with the most effective treatment, Helicobacter pylori eradication is difficult in some patients. Therefore, patients sometimes require acid-suppressive therapy without H. pylori eradication. It has been reported that ranitidine inhibits neutrophil activation, whereas famotidine does not. However, few studies have been published concerning the activation of neutrophils before and after treatment using clinical doses of histamine-2 receptor antagonists in patients with H. pylori infection.


OBJECTIVE
To examine the effects of neutrophil activation after treatment with three different histamine-2 receptor antagonists.


METHODS
This prospective, open-label, randomised, parallel-group study was conducted. Thirty patients with H. pylori infection were enrolled. These subjects were randomly assigned to receive one of the following treatments: (a) 150 mg ranitidine, (b) 20mg famotidine, or (c) 10 mg lafutidine b.d., for 4 weeks. Before and after histamine-2 receptor antagonist treatment, histological findings, myeloperoxidase activity, and interleukin-8 in the gastric mucosa were evaluated.


RESULTS
On the basis of the histological findings between before and after histamine-2 receptor antagonist treatment, no significant differences were found in any groups. Similarly, there were no significant differences in myeloperoxidase activity or interleukin-8 levels.


CONCLUSIONS
In patients with H. pylori, when used at clinical doses, any histamine-2 receptor antagonists can be used without concerning about inhibition of neutrophil activation.
Fukuda
M
M
Division of Digestive Disease, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe, Hyogo 650-0017, Japan.
Shirasaka
D
D
Aoyama
N
N
Miki
I
I
Kachi
M
M
Morita
Y
Y
Tamura
T
T
Kasuga
M
M
D000081:Acetamides / Q000627:therapeutic use; D000328:Adult; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000150:complications*; D016480:Helicobacter pylori / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018375:Neutrophil Activation / Q000187:drug effects*; D009195:Peroxidase / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use
D000081:Acetamides; D006635:Histamine H2 Antagonists; D016209:Interleukin-8; D010880:Piperidines; D011725:Pyridines; C076948:lafutidine; D015738:Famotidine; D011899:Ranitidine; D009195:Peroxidase